{"id":"NCT03879135","sponsor":"Baxalta now part of Shire","briefTitle":"A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)","officialTitle":"A Phase 3b, Prospective, Open-Label, Uncontrolled, Multicenter Study on Long-Term Safety and Efficacy of rVWF in Pediatric and Adult Subjects With Severe Von Willebrand Disease (VWD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-01","primaryCompletion":"2025-01-30","completion":"2025-01-30","firstPosted":"2019-03-18","resultsPosted":"2025-09-03","lastUpdate":"2025-09-03"},"enrollment":38,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Von Willebrand Disease (VWD)"],"interventions":[{"type":"BIOLOGICAL","name":"rVWF","otherNames":["Vonvendi","Vonicog alfa"]},{"type":"BIOLOGICAL","name":"rFVIII","otherNames":["Octocog alfa","ADVATE"]}],"arms":[{"label":"On-Demand","type":"EXPERIMENTAL"},{"label":"Prophylaxis","type":"EXPERIMENTAL"}],"summary":"The main aim of the study is to check effectiveness of rVWF (vonicog alfa) prophylaxis based on the annualized bleeding rate (ABR) of spontaneous (not related to trauma) bleeding episodes in pediatric and adult participants during the first 12 months on study treatment.\n\nThe participants will be treated with rVWF for a maximum of 3 years. Their von Willebrand Disease will be treated according to Investigational product (IP) dosing directions.","primaryOutcome":{"measure":"Spontaneous Annualized Bleeding Rate (sABR)","timeFrame":"Up to 12 months","effectByArm":[{"arm":"Cohort 1: Prophylaxis","deltaMin":1.43,"sd":2.3894},{"arm":"Cohort 2: Prophylaxis","deltaMin":1.04,"sd":null},{"arm":"Cohort 3: Prophylaxis","deltaMin":0,"sd":null},{"arm":"Cohort 4: Prophylaxis","deltaMin":3.022,"sd":2.4746}],"pValues":[]},"eligibility":{"minAge":"0 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":null},"locations":{"siteCount":33,"countries":["United States","Austria","France","Germany","Italy","Netherlands","Russia","Spain","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/5f6b5fe84db2bf003ab47b19"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":10},"commonTop":["COVID-19","Headache","Upper respiratory tract infection","Vomiting","Cough"]}}